Skip to main content

Table 3 Results of ORR by treatment schedule (Weekly vs. 3-Weekly) and by treatment drug (gemcitabine+docetaxel vs. gemcitabine+paclitaxel)

From: Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

  Treatment schedule Treatment drug
Weekly 3-weekly Gemcitabine + docetaxel Gemcitabine + paclitaxel
(N= 117) (N= 121) (N= 117) (N= 121)
  N(%) N(%) N(%) N(%)
Complete response (CR) 8 (6.8) 7 (5.8) 6 (5.1) 9 (7.4)
Partial response (PR) 51 (43.6) 34 (28.1) 45 (38.5) 40 (33.1)
Stable disease (SD) 28 (23.9) 50 (41.3) 38 (32.5) 40 (33.1)
Progressive disease (PD) 25 (21.4) 16 (13.2) 21 (17.9) 20 (16.5)
Not available 1 (0.9) 2 (1.7) 1 (0.9) 2 (1.7)
Not assessed 4 (3.4) 12 (9.9) 6 (5.1) 10 (8.3)
ORR (CR + PR) 59 (50.4) 41 (33.9) 51 (43.6) 49 (39.8)
Odds Ratio (95% CI); p value 0.504 (0.299-0.850); 0.010 0.882 (0.523-1.488); 0.639
  1. CI: Confidence Interval, ORR: Overall Response Rate; unadjusted odds ratio are presented in the table.